Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Advanced Therapy Medicinal Products CDMO Market Variables, Trends, and Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Rising number of clinical trials for ATMPs
3.1.1.2 Increasing outsourcing activities
3.1.1.3 Growing awareness of the treatment
3.1.2 Market Restraint Analysis
3.1.2.1 Stringent regulatory approvals
3.1.2.2 High cost of outsourcing
3.2 Business Environment Analysis Tools
3.2.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.2.2 Porter’s Five Forces Analysis
Chapter 4 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Product, 2018 – 2030 (USD Billion)
4.1 Advanced Therapy Medicinal Products CDMO market: Product Movement Analysis
4.2 Gene Therapy
4.2.1 Gene therapy market estimates and forecast, 2018 – 2030 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market estimates and forecast, 2018 – 2030 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market estimates and forecast, 2018 – 2030 (USD Billion)
4.5 Others
4.5.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 5 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Phase, 2018 – 2030 (USD Billion)
5.1 Advanced Therapy Medicinal Products CDMO market: Phase movement analysis
5.2 Phase 1
5.2.1 Phase 1 market estimates and forecast, 2018 – 2030 (USD Billion)
5.3 Phase 2
5.3.1 Phase 2 market estimates and forecast, 2018 – 2030 (USD Billion)
5.4 Phase 3
5.4.1 Phase 3 market estimates and forecast, 2018 – 2030 (USD Billion)
5.5 Phase 4
5.5.1 Phase 4 market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 6 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Indication, 2018 – 2030 (USD Billion)
6.1 Advanced therapy medicinal products CDMO market: Indication movement analysis
6.2 Oncology
6.2.1 Oncology market estimates and forecast, 2018 – 2030 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market estimates and forecast, 2018 – 2030 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market estimates and forecast, 2018 – 2030 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market estimates and forecast, 2018 – 2030 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market estimates and forecast, 2018 – 2030 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market estimates and forecast, 2018 – 2030 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market estimates and forecast, 2018 – 2030 (USD Billion)
6.9 Immunology & Inflammation
6.9.1 Immunology & inflammation market estimates and forecast, 2018 – 2030 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market estimates and forecast, 2018 – 2030 (USD Billion)
6.11 Hematology
6.11.1 Hematology market estimates and forecast, 2018 – 2030 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market estimates and forecast, 2018 – 2030 (USD Billion)
6.13 Others
6.13.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 7 Advanced Therapy Medicinal Products CDMO Market: Regional Market Analysis, 2018 – 2030 (USD Billion)
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Advanced therapy Medicinal products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.10 Rest of Europe Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Advanced Therapy Medicinal Prodcut CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Austrlia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.8 Rest of Asia Pacific Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.2 KEY Regional DYNAMICS
7.4.2.1 Latin America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.8 Rest of LATAM Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.2 KEY regional DYNAMICS
7.5.2.1 Middle East & Africa advanced therapy medicinal products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.9 Rest of MEA Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 8 Advanced Therapy Medicinal Products CDMO Market: Competitive Analysis
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 CELONIC Group
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Product Benchmarking
8.2.2.3 Strategic Initiatives
8.2.3 Rentschler Biopharma SE
8.2.3.1 Company Overview
8.2.3.2 Product Benchmarking
8.2.3.3 Strategic Initiatives
8.2.4 AGC Biologics
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Catalent, Inc.
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.6 Lonza
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.7 WuXi Advanced Therapies
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Minaris Regenerative Medicine
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking
8.2.8.3 Strategic Initiatives
8.2.9 Patheon, Inc.
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.10 Cell and Gene Therapy Catapult (CGT Catapult)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
